Report: IL-17 Therapies Target PsO and More, Poised for Growth

07/29/2025

Key Takeaways

  • IL-17 inhibitors are projected for steady growth through 2034, driven by indication expansion and advanced biologics.

  • New agents like izokibep and sonelokimab are showing promise in psoriatic arthritis and hidradenitis suppurativa.

  • Market pressures include biosimilar competition and payer scrutiny, but innovation in delivery and targeting may offset challenges.

The interleukin-17 (IL-17) inhibitors market is expected to see sustained growth through 2034, driven primarily by next-gen agents and expanding indications in dermatology and rheumatology, according to a new report.

Novel agents such as sonelokimab and izokibep are expected to reshape the treatment landscape by offering improved tissue penetration and efficacy over existing IL-17 inhibitors like secukinumab (Cosentyx) and ixekizumab (Taltz). Clinical data presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting supported this trend. UCB’s bimekizumab (Bimzelx), for instance, demonstrated durable benefit in moderate-to-severe plaque psoriasis across six posters.

Key industry players filling in the IL-17 pipeline include MoonLake Immunotherapeutics, Affibody Medical AB, SFA Therapeutics, DICE Therapeutics, and Eli Lilly. In April 2025, Affibody reported positive phase 2 results for izokibep in psoriatic arthritis (PsA), showing improvements in both joint and skin symptoms. SFA’s oral candidate, SFA-002, demonstrated favorable safety and no recurrence in a phase 1b psoriasis (PsO) trial.

IL-17 therapies have become a cornerstone in treating plaque PsO, PsA, and axial spondyloarthritis, according to the report, adding that expansion into hidradenitis suppurativa (HS) and palmoplantar pustulosis is a potential future area of growth. Market pressures include competition from biosimilars, payer constraints, and emerging oral agents.

“The anticipated launch of these emerging therapies are poised to transform the interleukin-17 inhibitors market landscape,” the authors wrote in the report. “They are expected to reshape the interleukin-17 inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.”

Source: PR Newsire press release, July 21, 2025.

Register

We're glad to see you're enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free